NASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Forecast, Price & News $91.30 +3.34 (+3.80%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$89.17▼$91.3850-Day Range$69.96▼$110.5952-Week Range$64.33▼$134.52Volume264,199 shsAverage Volume421,255 shsMarket Capitalization$5.23 billionP/E RatioN/ADividend YieldN/APrice Target$146.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Ascendis Pharma A/S MarketRank™ ForecastAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside62.2% Upside$148.09 Price TargetShort InterestBearish7.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.55) to ($8.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector434th out of 983 stocksPharmaceutical Preparations Industry205th out of 486 stocks 4.4 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $148.09, Ascendis Pharma A/S has a forecasted upside of 62.2% from its current price of $91.30.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.73% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 13.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASND. Previous Next 1.8 News and Social Media Coverage News SentimentAscendis Pharma A/S has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ascendis Pharma A/S this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($10.55) to ($8.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -8.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -8.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAscendis Pharma A/S has a P/B Ratio of 29.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ascendis Pharma A/S (NASDAQ:ASND) StockAscendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.Read More Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Stock News HeadlinesJune 4, 2023 | americanbankingnews.comWedbush Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $187.00June 2, 2023 | markets.businessinsider.comAscendis Pharma (ASND) Gets a Buy from Berenberg BankJune 4, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...June 2, 2023 | fool.comAscendis Pharma A/s (NASDAQ: ASND)June 2, 2023 | markets.businessinsider.comAscendis Pharma (ASND) Receives a Buy from WedbushJune 1, 2023 | msn.comCantor Fitzgerald Reiterates Ascendis Pharma A (ASND) Overweight RecommendationJune 1, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Ascendis PharmaMay 31, 2023 | markets.businessinsider.comAscendis Pharma (ASND) Receives a Buy from Goldman SachsJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 31, 2023 | finance.yahoo.comAscendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product CandidatesMay 31, 2023 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Short Interest Up 13.6% in MayMay 25, 2023 | finance.yahoo.comAscendis Pharma to Host Oncology Program Update on May 31May 23, 2023 | americanbankingnews.comAnalysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $147.33May 21, 2023 | benzinga.comAscendis Shareholder NoticeMay 18, 2023 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Research Coverage Started at StockNews.comMay 16, 2023 | benzinga.comAscendis Investor AlertMay 13, 2023 | finance.yahoo.comAscendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023May 13, 2023 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) to Post Q2 2023 Earnings of ($2.45) Per Share, Wedbush ForecastsMay 10, 2023 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by StockNews.comMay 9, 2023 | seekingalpha.comAscendis Pharma added to Wedbush's best ideas listMay 8, 2023 | msn.comWedbush Maintains Ascendis Pharma A (ASND) Outperform RecommendationMay 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Surgery Partners (SGRY) and Karuna Therapeutics (KRTX)May 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Editas Medicine (EDIT) and Tiziana Life Sciences (TLSA)May 4, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Ascendis Pharma A/S Decreased by SVB Leerink (NASDAQ:ASND)May 3, 2023 | finance.yahoo.comAscendis Pharma to Participate in the BofA Securities 2023 Health Care ConferenceMay 3, 2023 | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Ascendis Pharma A/S (NASDAQ:ASND) RevenuesMay 2, 2023 | msn.comAscendis Pharma Q1 Earnings: Skytrofa Soars, PTH Hurdles Yet To ClearSee More Headlines ASND Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASND Company Calendar Last Earnings4/27/2023Today6/03/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASND CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees639Year FoundedN/APrice Target and Rating Average Stock Price Forecast$148.09 High Stock Price Forecast$187.00 Low Stock Price Forecast$92.00 Forecasted Upside/Downside+59.9%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($10.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,450,000.00 Net Margins-721.72% Pretax Margin-720.35% Return on Equity-150.65% Return on Assets-48.12% Debt Debt-to-Equity Ratio2.87 Current Ratio4.08 Quick Ratio3.32 Sales & Book Value Annual Sales$53.93 million Price / Sales97.06 Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book29.17Miscellaneous Outstanding Shares57,330,000Free Float34,397,000Market Cap$5.23 billion OptionableOptionable Beta0.52 Key ExecutivesJan Møller MikkelsenPresident, CEO & Executive DirectorScott Thomas SmithChief Financial Officer & Senior Vice PresidentKennett SprogøeSenior Vice President, Head-Innovation & ResearchBirgitte VolckSVP, Head-Clinical Development & Medical AffairsStina SingelSenior Vice President & Head-Clinical DevelopmentKey CompetitorsOrganon & Co.NYSE:OGNAlkermesNASDAQ:ALKSCerevel TherapeuticsNASDAQ:CEREMadrigal PharmaceuticalsNASDAQ:MDGLIVERIC bioNASDAQ:ISEEView All CompetitorsInstitutional OwnershipPrelude Capital Management LLCBought 700 shares on 6/1/2023Ownership: 0.014%ProShare Advisors LLCSold 671 shares on 5/26/2023Ownership: 0.007%Putnam Investments LLCBought 34,453 shares on 5/22/2023Ownership: 1.292%Thrivent Financial for LutheransBought 1,918 shares on 5/17/2023Ownership: 0.222%Geode Capital Management LLCBought 541 shares on 5/16/2023Ownership: 0.090%View All Institutional Transactions ASND Stock - Frequently Asked Questions Should I buy or sell Ascendis Pharma A/S stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASND shares. View ASND analyst ratings or view top-rated stocks. What is Ascendis Pharma A/S's stock price forecast for 2023? 11 brokers have issued 12 month price targets for Ascendis Pharma A/S's shares. Their ASND share price forecasts range from $92.00 to $187.00. On average, they expect the company's share price to reach $148.09 in the next year. This suggests a possible upside of 62.2% from the stock's current price. View analysts price targets for ASND or view top-rated stocks among Wall Street analysts. How have ASND shares performed in 2023? Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND shares have decreased by 25.2% and is now trading at $91.30. View the best growth stocks for 2023 here. Are investors shorting Ascendis Pharma A/S? Ascendis Pharma A/S saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,430,000 shares, an increase of 13.6% from the April 30th total of 3,900,000 shares. Based on an average trading volume of 806,600 shares, the short-interest ratio is currently 5.5 days. View Ascendis Pharma A/S's Short Interest. When is Ascendis Pharma A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our ASND earnings forecast. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Thursday, April, 27th. The biotechnology company reported ($2.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.84) by $0.72. The biotechnology company had revenue of $36.04 million for the quarter, compared to analysts' expectations of $24.53 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 150.65% and a negative net margin of 721.72%. What ETFs hold Ascendis Pharma A/S's stock? ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), American CenturyFocused Dynamic Growth ETF (FDG), Global X Guru Index ETF (GURU), First Trust NASDAQ BuyWrite Income ETF (FTQI), Harbor Disruptive Innovation ETF (INNO) and Putnam Sustainable Future ETF (PFUT). What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA). When did Ascendis Pharma A/S IPO? (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. What is Ascendis Pharma A/S's stock symbol? Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND." Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (11.94%), FMR LLC (8.99%), Price T Rowe Associates Inc. MD (5.88%), Avoro Capital Advisors LLC (5.80%), Westfield Capital Management Co. LP (5.49%) and Wellington Management Group LLP (5.12%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ascendis Pharma A/S's stock price today? One share of ASND stock can currently be purchased for approximately $91.30. How much money does Ascendis Pharma A/S make? Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.23 billion and generates $53.93 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($10.49) on an earnings per share basis. How many employees does Ascendis Pharma A/S have? The company employs 639 workers across the globe. How can I contact Ascendis Pharma A/S? Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010. This page (NASDAQ:ASND) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.